Australian & New Zealand Childrens Haematology/Oncology Group
Study Title
Nivolumab and DAY101 for the treatment of newly diagnosed or recurrent craniopharyngioma in children and young adults
Protocol ID
PNOC029
Disease (Sub Disease)
Craniopharyngioma
Diagnosis Stage
Newly diagnosed
Relapsed/Refractory
Relapsed/Refractory
Sponsor
Australian & New Zealand Children's Haematology/Oncology Group
Collaborators
Bristol-Myers Squibb
Day One Biopharmaceuticals, Inc.
Day One Biopharmaceuticals, Inc.
Links
Trial Status
Preparing to Open
Study Type
Treatment
Phase
Phase 2
Age Eligibility
1 Year to 39 Years
International registry ID's
NCT05465174
| Study Title | Nivolumab and DAY101 for the treatment of newly diagnosed or recurrent craniopharyngioma in children and young adults |
|---|---|
| Protocol ID | PNOC029 |
| Disease (Sub Disease) | Craniopharyngioma |
| Diagnosis Stage | Newly diagnosed Relapsed/Refractory |
| Sponsor | Australian & New Zealand Children's Haematology/Oncology Group |
| Collaborators | Bristol-Myers Squibb/ Day One Biopharmaceuticals, Inc. |
| Links | https://clinicaltrials.gov/ct2/show/NCT05465174 |
| Trial Status | Preparing to Open |
| Study Type | Treatment |
| Phase | Phase 2 |
| Age Eligibility | 1 Year to 39 Years |
| International registry ID's | NCT05465174 |